Network Pharmacology-Based Identification of Key Mechanisms of Xihuang Pill in the Treatment of Triple-Negative Breast Cancer Stem Cells
Xihuang pill, an approved Chinese medicine formula (state medical permit number. Z11020073), is a commonly used adjuvant drug for cancer patients in China. Xihuang pill has a satisfactory effect in treating breast cancer in clinics, especially triple-negative breast cancer (TNBC), which is the most...
Saved in:
Main Authors: | Yu-Zhu Zhang (Author), Jia-Yao Yang (Author), Rui-Xian Wu (Author), Chen Fang (Author), Hai Lu (Author), Hua-Chao Li (Author), Dong-Mei Li (Author), Hua-Li Zuo (Author), Li-Ping Ren (Author), Xiao-Yuan Liu (Author), Rui Xu (Author), Jia-Huai Wen (Author), Hsien-Da Huang (Author), Ri Hong (Author), Qian-Jun Chen (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guidelines for the clinical application of the Xihuang pill for the prevention and treatment of breast hyperplasia diseases
by: Hongmei Tang, et al.
Published: (2024) -
Therapeutic potential of Xihuang Pill in colorectal cancer: Metabolomic and microbiome-driven approaches
by: Chen Zhang, et al.
Published: (2024) -
Exploring the Regulation Mechanism of Xihuang Pill, Olibanum and β-Boswellic Acid on the Biomolecular Network of Triple-Negative Breast Cancer Based on Transcriptomics and Chemical Informatics Methodology
by: Kailin Yang, et al.
Published: (2020) -
Exploring the Pharmacological Mechanisms of Xihuang Pills Against Prostate Cancer via Integrating Network Pharmacology and Experimental Validation In Vitro and In Vivo
by: Yongrong Wu, et al.
Published: (2022) -
Gallic acid suppresses the progression of triple-negative breast cancer HCC1806 cells via modulating PI3K/AKT/EGFR and MAPK signaling pathways
by: Si Lin, et al.
Published: (2022)